CN115011532A - Lactobacillus paracasei JY062 preparation and preparation method and application thereof - Google Patents
Lactobacillus paracasei JY062 preparation and preparation method and application thereof Download PDFInfo
- Publication number
- CN115011532A CN115011532A CN202210944148.5A CN202210944148A CN115011532A CN 115011532 A CN115011532 A CN 115011532A CN 202210944148 A CN202210944148 A CN 202210944148A CN 115011532 A CN115011532 A CN 115011532A
- Authority
- CN
- China
- Prior art keywords
- preparation
- bacterial
- culture medium
- lactobacillus paracasei
- mrs
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/225—Lactobacillus
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Mycology (AREA)
- Zoology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Biotechnology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Biomedical Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
The invention discloses a preparation method of a lactobacillus paracasei JY062 preparation, which comprises the following steps: step one, lactobacillus paracasei JY062 (Lactobacillus paracasei JY 062) is inoculated to an MRS culture medium in an inoculation amount of 5 percent, after the MRS culture medium is cultured for 16-18 h at the temperature of 32-37 ℃, three regions are scribed on the MRS solid culture medium, a single colony is selected to be placed in the MRS culture medium after the culture, after two generations of subculture, the colony is centrifuged at 6000-8000 r/min for at least 10 minutes, fermentation supernatant is collected, and bacterial sludge is washed at least twice by PBSThen re-suspending with PBS to make viable count of the bacterial suspension at least 10 9 CFU/mL. The invention also discloses a preparation obtained by the preparation method and application thereof. The preparation obtained by the invention has higher viable count and good application effect.
Description
Technical Field
The invention relates to a lactobacillus paracasei JY062 preparation, a preparation method and an application thereof, in particular to a lactobacillus paracasei JY062 preparation for improving hepatic injury caused by glycolipid metabolic disturbance, a preparation method and an application thereof, and belongs to the technical field of microorganisms.
Background
Glycolipid metabolic disorders (GLMD) are a series of diseases which cause sugar and lipid metabolism disorders under the influence of genetic, psychological and environmental factors. The main pathological manifestations of GLMD are neuroendocrine dysfunction, Insulin Resistance (IR), metabolic inflammation and gut flora disorders. The main clinical manifestations of the disease include Type 2 Diabetes mellitis, T2DM, hyperlipidemia, obesity, Non-alcoholic fatty liver disease (NAFLD), and Atherosclerosis (AS), which may occur singly or in combination. The cause of glycolipid metabolic disorder diseases is complex, the symptoms of the glycolipid metabolic disorder diseases continuously change along with the change of the disease course, especially, the occurrence of complications brings more obstacles to the treatment of the diseases, the clinical diagnosis and treatment mainly comprise single disease species and branch diagnosis and treatment, the focus is mainly on a specific disease, and the prevention and control effect of the diseases is not ideal if comprehensive integral treatment is needed when the existence of a plurality of disease complications is ignored. Clinically, combined use of hypoglycemic and hypolipidemic drugs such as sulfonylureas, biguanides, alpha-glucosidase inhibitors and the like is generally adopted, but some side effects of the drugs limit the long-term clinical application of the drugs, and the hypoglycemic and hypolipidemic drugs cannot improve liver injury. Therefore, the development of a natural and safe novel hypoglycemic agent or adjuvant therapy agent becomes important.
At present, a large number of researches show that probiotics can regulate and control the homeostasis of intestinal tracts of organisms and relieve glycolipid metabolic disorders of animal models or clinical patients to different degrees by reducing inflammatory reactions, relieving oxidative stress reactions, improving intestinal barriers, enhancing immunoregulation and the like. In recent years, with the intensive study on the interaction between a host and an intestinal flora, the probiotics are considered to be feasible and have important research value for relieving GLMD by mediating the intestinal flora of patients. The invention develops the lactobacillus paracasei capable of improving glycolipid metabolic disturbance.
Disclosure of Invention
The invention aims to provide a preparation method of a lactobacillus paracasei JY062 preparation, and the preparation obtained by the method has higher viable count and good application effect.
Meanwhile, the invention provides a preparation obtained by the preparation method of the lactobacillus paracasei JY062 preparation.
Meanwhile, the invention provides application of a Lactobacillus paracasei JY062 preparation in preparation of a medicine for improving hepatic injury caused by glycolipid metabolic disturbance.
Meanwhile, the invention provides application of the lactobacillus paracasei JY062 preparation in preparation of a medicine for improving glycolipid metabolic disorder.
In order to solve the technical problems, the technical scheme adopted by the invention is as follows:
the invention discloses a preparation method of a lactobacillus paracasei JY062 preparation, which comprises the following steps:
step one, Lactobacillus paracasei JY062 (B)Lactobacillus paracasei JY 062) is inoculated to an MRS culture medium in an inoculation amount of 5 percent, after the MRS culture medium is cultured for 16-18 h at the temperature of 32-37 ℃, three regions are scribed on the MRS solid culture medium, a single bacterial colony is selected to be placed in the MRS culture medium after the culture, after two generations of subculture, the bacterial colony is centrifuged at least for 10 min at 6000-8000 r/min, fermentation supernatant is collected, after the bacterial mud is washed at least twice by PBS, the bacterial mud is re-suspended by PBS, so that the viable count of the bacterial suspension at least reaches 10 9 CFU/mL;
Step two, centrifuging the bacterial suspension, collecting bacterial sludge, adding the component I of the preparation solution into the bacterial sludge, wherein the volume ratio of the bacterial sludge to the component I is 1:4, and fully and uniformly mixing to prepare a bacterial suspension II;
step three, adding the component II of the preparation solution into the bacterial suspension II, and uniformly mixing to obtain a bacterial suspension III;
step four, placing the bacterial suspension III in a constant-temperature water bath kettle, standing for at least 20 min at 35-37 ℃, and performing vacuum freeze drying to obtain bacterial powder;
the first component of the preparation solution comprises the following components in percentage by mass: 10-20% of skim milk, 8-12% of trehalose, 4-6% of maltodextrin, 2-4% of sodium L-glutamate and the balance of water;
the second component of the preparation solution comprises: 2 '-fucosyllactose (2' -FL), wherein the adding volume of the 2 '-fucosyllactose (2' -FL) is 1-3% of that of the first component, and the second component is a 5-10wt% 2 '-fucosyllactose (2' -FL) aqueous solution;
the viable count of the bacterial powder is at least 1.23 × 10 11 CFU/mL。
The MRS culture medium has the following formula: 5.0 g of peptone, 10.0 g of tryptone, 5.0 g of beef extract, 5.0 g of yeast powder, 20.0 g of glucose, 2.6 g of diammonium hydrogen citrate, 2.0 g of dipotassium hydrogen phosphate, 5.0 g of sodium acetate, 0.58 g of magnesium sulfate, 0.25 g of manganese sulfate and Tween-801 mL; the preparation method of the MRS culture medium comprises the following steps: accurately weighing the reagents according to the formula, fixing the volume in 1000 mL of distilled water, uniformly mixing, adjusting the pH value to 5.8, sterilizing at 121 ℃ for 15 min, and storing at 4 ℃ for later use.
The MRS solid culture medium has the following formula: 10.0 g of peptone, 8.0 g of beef extract, 4.0 g of yeast powder, 20.0 g of glucose, 2.0 g of diammonium hydrogen citrate, 2.0 g of dipotassium hydrogen phosphate, 5.0 g of sodium acetate, 0.2 g of magnesium sulfate, 0.04 g of manganese sulfate, 14.0 g of agar and Tween-801 mL; the preparation method of the MRS solid culture medium comprises the following steps: accurately weighing the above reagents according to the above formula, fixing the volume in 1000 mL of distilled water, mixing well, adjusting pH to 5.8, sterilizing at 121 deg.C for 15 min,
putting into a constant temperature water bath kettle at 60 ℃ for standby.
The vacuum freeze drying process comprises the following steps: placing the treated bacterial suspension III into an ultra-low temperature refrigerator for pre-freezing at the temperature of minus 80 ℃ for 2 hours; and (3) starting a vacuum freeze dryer in advance, putting the pre-frozen bacterial suspension III on a partition plate of the vacuum freeze dryer, vacuumizing and freeze-drying, wherein the temperature of a cold trap of the freeze dryer is-53.2 ℃, the vacuum degree is 0.162 mbar, and the time is 24 hours.
The PBS is 0.1mol/L, and the pH value is 6.8.
Meanwhile, the invention discloses a preparation obtained according to the preparation method.
Meanwhile, the invention discloses application of the preparation in preparing a medicament for improving hepatic injury caused by glycolipid metabolic disturbance.
Meanwhile, the invention discloses application of the preparation in preparing a medicament for improving glycolipid metabolic disorder.
The invention has the following beneficial effects:
the invention discloses lactobacillus paracasei JY062, and belongs to the technical field of food microorganisms. The lactobacillus paracasei JY062 preparation used by the invention comprises the following components in a preparation formula according to the total mass fraction of 100 percent: the food comprises 10-20% of skim milk, 8-12% of trehalose, 4-6% of maltodextrin, 2-4% of L-sodium glutamate and the balance of water; the second component of the preparation formula is 2 '-fucosyllactose (2' -FL), and the adding volume of the 2 '-fucosyllactose (2' -FL) is 1-3% of that of the first component; the 2 '-fucosyllactose (2' -FL) has good probiotic function and synergistic probiotic effect, and can improve the activity of Lactobacillus paracasei JY062 bacteria in the preparation. The lactobacillus used in the invention is JY062 which is separated from Tibetan dairy products and is used for improving the hepatic injury of mice with glycolipid metabolic disturbance induced by high-sugar and high-fat diet; obtaining liver and serum samples, and detecting the fat factor and insulin level and gene expression related to fat-insulin axis path to evaluate the influence of lactobacillus paracasei JY062 on glycolipid metabolism disorder; the result shows that Lactobacillus paracasei JY062 activates the expression of the APN-AMPK signal path, reduces the expression of SREBP-1c, ACC and FAS in lipid metabolism, and up-regulates the expression of GLUT-4 and PGC-1 alpha in sugar metabolism, thereby improving the glycolipid index and further relieving liver injury.
Drawings
FIG. 1 is a graph showing the results of measurement of viable count of a preparation;
FIG. 2 is a graph of the change in body weight and blood glucose of a mouse, wherein a) is the body weight of the mouse and b) is the blood glucose of the mouse;
FIG. 3 is a graph of the change in glucose tolerance in mice, wherein a) is the blood glucose level in mice, and b) is the glucose tolerance in mice;
FIG. 4 is a graph of the change in mouse adipokine and insulin, wherein a) is the leptin value (LEP), b) is the adiponectin value (ADPN), c) is the insulin value (INS), d) is the glucagon-like peptide-1 value (GLP-1), e) is the free fatty acid value (FFA);
FIG. 5 is a graph showing changes in gene expression of adiponectin-related genes (adipoQ and Adipor-2), AMPK, lipid metabolism-related genes (SREBP-1 c, FAS, ACC), and carbohydrate metabolism-related genes (GLUT-4, PGC-1. alpha.) in mouse liver, wherein a) is the adipoQ gene, b) is the Adipor-2 gene, c) is the AMPK gene, d) is the SREBP-1c gene, e) is the FAS gene, f) is the ACC gene, g) is the GLUT-4 gene, and h) is the PGC-1. alpha. gene;
FIG. 6 is a graph of HE staining of mouse liver, a) is liver of N groups of mice; b) liver of HFD group mice; c) the liver of LPL group mice; d) liver of LPM group mouse; e) liver of mice in LPH group; thin arrows represent hepatocyte edema; thick arrows represent steatosis;
FIG. 7 is a graph of HE staining of mouse pancreas, a) is N groups of mouse pancreas; b) pancreas of mice in HFD group; c) the pancreas of mice in LPL group; d) the pancreas of mice in LPM group; e) the pancreas of mice in LPH group.
Detailed Description
The present invention will be further described with reference to the accompanying drawings.
In the invention, the Latin name of the lactobacillus paracasei JY062 isLactobacillus paracasei JY062, deposited in the northeast agriculture university dairy products focus laboratory, the Lactobacillus paracasei JY062 of the invention has prior art sources: adhesion and tolerance evaluation of high-yield exopolysaccharide hypoglycemic lactobacillus paracasei JY062 (TD 062) [ J]The chinese dairy industry, 2022, 50 (4).
Example 1
1.1 Experimental reagents
(1) MRS medium
For culturing lactobacillus paracasei JY062, the formula of the culture medium is as follows: 5.0 g of peptone, 10.0 g of tryptone, 5.0 g of beef extract, 5.0 g of yeast powder, 20.0 g of glucose, 2.6 g of diammonium hydrogen citrate, 2.0 g of dipotassium hydrogen phosphate, 5.0 g of sodium acetate, 0.58 g of magnesium sulfate, 0.25 g of manganese sulfate and Tween-801 mL; the preparation method of the MRS culture medium comprises the following steps: accurately weighing the reagents according to the formula, fixing the volume in 1000 mL of distilled water, uniformly mixing, adjusting the pH value to 5.8, sterilizing at 121 ℃ for 15 min, and storing at 4 ℃ for later use.
(2) High-fat high-sugar feed
The high-fat high-sugar feed comprises 65% of basic feed, 20% of cane sugar, 10% of lard oil, 2.5% of cholesterol, 1% of sodium cholate, 1.5% of egg, sesame oil, peanut and the like which are mixed and blended.
(3) Adipokine, insulin Elisa kit (shanghai xinle); PrimeScript RT reagent Kit, SYBR Premix Ex TaqTM II (Dalianbao Biotechnology engineering Co., Ltd.).
(4) Gene primer:
TABLE 1 Gene primer sequences
1.2 Lactobacillus paracasei JY062 culture
Inoculating lactobacillus paracasei JY062 to an MRS culture medium in an inoculation amount of 5%, culturing at 37 ℃ for 18 hours, scribing a three region on the MRS solid culture medium, selecting a single bacterial colony in the MRS culture medium after culturing, centrifuging at 6000 r/min for 10 min after subculturing two generations, collecting fermentation supernatant, washing bacterial sludge twice by PBS (0.1 mol/L, pH value of 6.8), and then re-suspending by PBS to enable the viable count of bacterial suspension to reach about 10 9 CFU/mL。
1.3 preparation of Lactobacillus paracasei JY062 preparation
(1) Preparation of a bacterial suspension of the preparation
Optimization group 1: the Lactobacillus paracasei JY062 is cultured according to the conditions, so that the viable count of the bacterial suspension reaches about 10 9 CFU/mL, centrifuging, concentrating, collecting, adding the prepared preparation solution (2 '-fucosyllactose (2' -FL) mixed therein), and mixing to obtain bacterial suspension. Placing the bacterial suspension in a constant-temperature water bath kettle, standing at 37 ℃ for 20 min, and aseptically transferring into a glass plate.
Optimization group 2: the Lactobacillus paracasei JY062 is cultured according to the conditions, so that the viable count of the bacterial suspension reaches about 10 9 CFU/mL, after centrifugation, concentration and collectionAdding the prepared preparation solution (2 '-fucosyllactose (2' -FL) is not mixed) into the bacterial sludge, fully mixing to prepare bacterial suspension, adding 5wt% of dissolved 2 '-fucosyllactose (2' -FL) and further mixing. Placing the bacterial suspension in a constant-temperature water bath kettle, standing at 37 ℃ for 20 min, and aseptically transferring into a glass plate.
Specifically, the first component of the preparation solution comprises the following components in percentage by mass: 15% of skim milk, 10% of trehalose, 5% of maltodextrin, 3% of sodium L-glutamate and the balance of water;
the second component of the preparation solution comprises: 2 '-fucosyllactose (2' -FL), said 2 '-fucosyllactose (2' -FL) being added in a volume corresponding to 2% of component one.
Control group: the conditions were the same as those in the optimized group for the ordinary lyoprotectant without the addition of 2 '-fucosyllactose (2' -FL).
(2) Vacuum freeze drying method
And putting the prepared bacterial suspension into an ultra-low temperature refrigerator for pre-freezing at the temperature of minus 80 ℃ for 2 hours. And (4) starting a vacuum freeze dryer in advance, quickly putting the pre-frozen sample on a partition plate, and vacuumizing for freeze drying. The temperature of the cold trap of the freeze dryer is-53.2 ℃, the vacuum degree is 0.162 mbar, and the time is 24 hours. And (4) collecting the bacterial powder after freeze-drying is finished, and determining the bacterial activity in the bacterial powder.
(3) Carrying out 10-time serial gradient dilution on the freeze-dried bacterial powder by using sterile PBS solution, adding 1 mL of diluent into a culture dish after reaching proper gradient, and determining the viable count by adopting a plate counting method, wherein the culture medium is MRS agar. The culture dish is placed in an incubator at 37 ℃ for 48 hours for data statistics.
(4) Viable count of lactobacillus paracasei JY062 preparation: as can be seen from FIG. 1, the viable count obtained by optimizing the formulation of group 2 was 1.23X 10, which is higher 11 CFU/mL, and has good application effect.
1.4 mouse protocol
60 male C57BL/6J mice were selected for the experiment, and the mice were aged about three weeks and were randomly divided into 5 groups: n: (normal group), HFD: model group, LPH: high dose lactobacillus paracasei JY062 preparationGroup, LPM: medium dose lactobacillus paracasei JY062 formulation group and LPL: low dose lactobacillus paracasei JY062 formulation group. The temperature of the rat room is 22 +/-2 ℃, the humidity is 55 +/-5%, the rat room is alternately used for 12 hours day and night, and the basal feed is adaptively fed for one week. From the second week on, the HFD, LPL, LPM and LPH groups were fed with high fat and high sugar diet. After three weeks of modeling, the random blood sugar of the mice is measured, and the mice with blood sugar value higher than 11.1 mmol/L are successful model mice. Then, the LPH, LPM and LPL groups were gavaged with 10 mL/kg at 9:00 am every day in 10 mL/kg doses 9 、10 8 And 10 7 The bacterial suspension of the Lactobacillus paracasei JY062 of CFU/mL and the normal saline with the same dosage for intragastric administration of the N and HFD groups.
In this example, the number of viable bacteria in the bacterial powder was 1.23X 10 11 CFU/mL, adding physiological saline to the bacterial powder for gradient dilution to 10 9 、10 8 And 10 7 CFU/mL; and (4) intragastrically filling the prepared bacterial suspension.
1.5 mouse body weight determination
Mouse body weights were measured and recorded weekly from the beginning of the first week to the end of the experiment.
As a result: the weight change of the mice in each group during the feeding period can be seen from fig. 2 a), the mice in the N groups are always on normal diet during the feeding period, and the weight of the mice in the group tends to increase first and then to be gentle. The body weight of the mice in the HFD group is increased by 25.5 g compared with that in the N group and is higher than that in the normal diet mice in the second to fourth weeks of the test, the body weight of the mice in the HFD group is increased by 45.50 percent compared with that in the N group, the body weight of the mice in the HFD group is continuously increased in the fifth to tenth weeks of the test, while the body weight of the mice in the LPL group, the LPM group and the LPH group of the Lactobacillus paracasei JY062 is increased slowly and is obviously lower than that in the HFD group, and the body weight of the mice in the LPL group, the LPM group and the LPH group is increased by 4.025 g, 3.57 g and 3.07 g and is lower than that in the HFD group (P <0.05) compared with that in the fourth week of the test. In conclusion, the lactobacillus paracasei JY062 has the effect of relieving the weight gain of the glycolipid metabolic disorder mice, and the effect of the high-dose lactobacillus paracasei JY062 is more obvious.
1.6 mouse blood glucose and oral glucose tolerance assays
1.6.1 mouse blood glucose assay: from the beginning of the first week to the end of the experiment, the body weight and Fasting plasma glucose (FBG) of the mice were measured at fixed time weekly, and before measurement the FBG values of the mice were measured after overnight Fasting without water deprivation. The results are shown in FIG. 2 b), the fasting plasma glucose of the mice in each group during the test period. From the figure, it can be observed that the blood glucose levels of the N groups of mice were stable throughout the test period. From the second to the fourth week of the experiment, there was no difference in blood glucose in the other groups compared to the N group; in the fifth week of the experiment, the blood glucose of the mice in the HFD group was significantly increased to 8.83 mmol/L, which indicates that the sugar metabolism of the mice was changed after feeding high-fat high-sugar diet. The HFD group of mice was consistently at high blood glucose levels for five to eleven weeks of the trial. The blood glucose levels in the LPL, LPM and LPH groups were less different than those in the HFD group at five to seven weeks of the study, while the blood glucose levels in the LPL, LPM and LPH groups were decreased compared with those in the HFD group at the eighth to eleventh weeks of the study. At the end of the eleventh week of the experiment, the blood glucose levels in LPL, LPM and LPH groups were 7.44 mmol/L, 7.00 mmol/L and 6.29 mmol/L, respectively, while the blood glucose level in HFD group was 9.17 mmol/L.
1.6.2 oral glucose tolerance test in mice: at the end of the experiment in the eleventh week, the mice were fasted overnight for 12 h without water deprivation, and 3 mice were selected to be given a 40% glucose solution and gavage at a volume of 5 mL/kg with a gavage standard of 2 g/kg glucose. Blood glucose levels were measured at fasting and glucose load 30 min, 60 min, 120 min, respectively, and the area under the glucose curve (AUC) was calculated.
As can be seen in FIG. 3 a), the blood glucose metabolism was normal after gastric gavage in the N groups of mice, the blood glucose level increased gradually first, reached a peak at 30 min, the maximum blood glucose value was 12.06 mmol/L, and then it decreased rapidly and approached the normal blood glucose value at 2 h (6.83 mmol/L). The results show that the islet cells of N groups of mice have normal functions and the organism has good regulating capacity for blood sugar. However, in the HFD, LPL, LPM and LPH group mice with high-sugar and high-fat diet intervention, after gastric lavage, the blood sugar level rapidly increased and peaked at 30 min, respectively 18.6 mmol/L, 17.0 mmol/L, 16.7 mmol/L and 14.7 mmol/L, which are all significantly different from the N group (P < 0.05). The blood sugar value of the mice shows a slow descending trend after 30 min, the blood sugar value of each group of mice does not recover to the initial level at 2 h, the blood sugar concentration of the HFD group of mice is still at a high level and is 12.6 mmol/L, the blood sugar value of the LPL group of mice, the LPM group of mice and the LPH group of mice is obviously lower than the blood sugar value of the HFD group of mice (P is less than 0.05), the blood sugar value of the LPL group of mice reaches 11.07 mmol/L at 2 h, the blood sugar value of the LPM group of mice reaches 9.53 mmol/L, and the blood sugar value of the LPH group of mice reaches 7.77 mmol/L. The result shows that the lactobacillus paracasei JY062 can obviously inhibit abnormal rise of blood sugar after the glucose is perfused into the stomach of a glycolipid metabolic disorder mouse, can normalize the function of islet cells, has dose dependence, and has the best effect of the high-dose lactobacillus paracasei JY 062.
According to the oral glucose tolerance curve, the area under the peak curve (AUC) is made, and the AUC can be used to represent the degree of impaired glucose tolerance, and the larger the AUC value, the more serious the degree of impaired glucose tolerance, and the result is shown in fig. 3 b). As can be seen from the figure, the AUC values of the HFD group are significantly higher than those of the N group. The AUC values increased by 62.41% compared with N group (P <0.05), which indicates abnormal blood glucose metabolism and impaired glucose tolerance in HFD group mice. Whereas AUC values of LPL, LPM and LPH groups were significantly reduced compared to HFD group (P <0.05), and AUC value of LPH group was lowest, reduced by 27.08% compared to HFD group. The result shows that the lactobacillus paracasei JY062 can enhance the glucose tolerance of the glycolipid metabolic disorder mouse body to a certain extent, the effect is dose dependent, and the effect of the high-dose lactobacillus paracasei JY062 is the best.
1.7 measurement of mouse fat factor and insulin
At the end of the experiment, five groups of mice were fasted overnight for 12 h, weighed, bled by the eyeballs, blood samples were centrifuged at 3000 Xg for 10 min at 4 ℃, and serum was collected and its content was determined according to the kit instructions.
As a result: as shown in fig. 4, after feeding with high-sugar and high-fat diet, the contents of Leptin (LEP), Insulin (INS), and Free Fatty Acid (FFA) in HFD group mice were significantly increased (P <0.05), respectively by 143%, 117%, and 68.8%, while the contents of Adiponectin (ADPN), glucagon-like peptide-1 (GLP-1) were significantly decreased (P <0.05), by 64.25%, and by 71.02%, compared to N group mice, while in LPL, LPM, and LPH group, the contents of Leptin (LEP), Insulin (INS), and Free Fatty Acid (FFA) were significantly decreased, and the contents of Adiponectin (ADPN), glucagon-like peptide-1 (GLP-1) were significantly increased (P <0.05), compared to HFD group mice; among them, the LPH group showed the best effect, and compared with the HFD group, the Leptin (LEP), Insulin (INS) and Free Fatty Acid (FFA) contents were reduced by 54.34%, 39.95% and 40.68%, and the Adiponectin (ADPN) and glucagon-like peptide-1 (GLP-1) contents were respectively increased by 153% and 135% (P < 0.05).
1.8 quantitative PCR analysis of mouse liver tissue
mRNA in mouse liver tissue was extracted according to the kit instructions and reverse-transcribed into cDNA, and the resulting cDNA was reacted according to the reaction system and reaction conditions shown in Table 2 below.
TABLE 2 Real-time RT-PCR reaction System
TABLE 3 Real-time RT-PCR reaction conditions
As a result: as shown in FIG. 5, the relative expression levels of adiponectin related genes (AdipoQ and AdipoR-2), AMPK, glucose metabolism related genes (GLUT-4 and PGC-1. alpha.) in the liver of the HFD group mice were significantly decreased (P <0.05), and the relative expression levels of the lipid metabolism related genes (SREBP-1 c, ACC and FAS) were significantly increased (P <0.05) compared to the N group mice after feeding the mice on the high-sugar high-fat diet. In the LPL, LPM and LPH groups, the relative gene expression levels of adiponectin-related genes (AdipoQ and AdipoR-2), AMPK, glucose metabolism-related genes (GLUT-4 and PGC-1. alpha.) were significantly increased (P <0.05), and the relative gene expression levels of lipid metabolism-related genes (SREBP-1 c, ACC and FAS) were significantly decreased (P <0.05) as compared with the HFD group, wherein the LPH group was most effective in that the relative gene expression levels of adiponectin-related genes (AdipoQ and AdipoR-2), AMPK, glucose metabolism-related genes (GLUT-4 and PGC-1. alpha.) were increased 182%, 202%, 384%, 138% and 185%, respectively, and the relative gene expression levels of lipid metabolism-related genes (SREBP-1 c, ACC and FAS) were decreased by 47.2%, 44.6% and 50.9% (P <0.05), respectively)
1.9 mouse liver and pancreas HE staining
Mouse liver and pancreatic tissues were fixed in 4% paraformaldehyde solution for 24H, then dehydrated, cleared, paraffin embedded, sectioned and stained (H & E). The samples were then imaged under an optical microscope and examined histologically.
As a result: the liver tissue structure of N mice is slightly abnormal, part of liver cells are slightly edematous, the nucleus is clear, and cytoplasm vacuoles as shown by a thin arrow in figure 6; inflammatory cell infiltration and steatosis are not seen in the liver parenchyma; the hepatic tissue structure of the mice in the HFD group is severely abnormal, large-area hepatic cell steatosis is caused, and a large number of lipid droplets with different sizes can be seen, as shown by thin arrows in figure 6; some cells were heavily edematous, the cells were swollen and the cytoplasm vacuolated, as indicated by the thick arrows in FIG. 6. Compared with the HFD group, after the different doses of the Lactobacillus paracasei JY062 preparation are dried, the edema and the steatosis degree of the liver cells are reduced, the arrangement of the liver cells is homogenized, the gap between the liver cells is reduced, and the effect of the LPH group is best similar to the liver cell state of the N groups of mice.
As shown in fig. 7, the pancreatic tissue structure of N groups of mice was clear, with no vacuolization and inflammatory cell infiltration; the islets are spherical cell cluster-like structures, are distributed among acini, have clear boundaries with surrounding glands, are regularly arranged in the cells in the islets, have higher cell density and are rich in cytoplasm; the islets of mice in the HFD group were distributed between the acini, with unclear boundaries with the surrounding glands, and the number of islets was also significantly reduced, with a large number of inflammatory cell infiltrates visible, as indicated by the arrows in FIGS. 7 b), 7 c). Compared with the HFD group, after different doses of the Lactobacillus paracasei JY062 preparation are dried, the islet cells are arranged regularly, the number of the islets is increased gradually, the boundaries of the islets and the surrounding glands are clear gradually, and partial telangiectasia phenomena occur in the M group, as shown by arrows in figure 7 d). The results show that the lactobacillus paracasei JY062 has a repairing effect on pancreas of mice with glycolipid metabolism disorder, is dose-dependent, and has the most obvious effect in an LPH group.
The Lactobacillus paracasei JY062 preparation selected by the invention has the capability of regulating and controlling the level of fat factors and insulin on a fat-insulin axis, and can lower the expression of SREBP-1c, ACC and FAS in lipid metabolism and up-regulate the expression of GLUT-4 and PGC-1 alpha in glucose metabolism through an APN-AMPK pathway to improve glycolipid disturbance, thereby relieving liver injury. The Lactobacillus paracasei JY062 preparation can be applied to the alleviation and prevention of multi-organ injury caused by glycolipid metabolic disorder, and provides theoretical reference for developing safe and effective probiotic related products which are easy to produce and store and have the effect of alleviating liver injury caused by glycolipid metabolic disorder.
Example 2
The purpose of this example is to provide a preparation method of lactobacillus paracasei JY062 preparation, including the following steps:
step one, lactobacillus paracasei JY062 (Lactobacillus paracasei JY 062) inoculating to an MRS culture medium by 5 percent of inoculation amount, after culturing for 16 h at 32 ℃, streaking three regions on the MRS solid culture medium, selecting a single bacterial colony in the MRS culture medium after culturing, centrifuging for 20 min at 8000r/min after subculturing for two generations, collecting fermentation supernatant, washing bacterial sludge by PBS, wherein the PBS is 0.1mol/L, the pH value is 6.8, after washing for three times, re-suspending by PBS, and enabling the viable count of bacterial suspension to reach 10 9 CFU/mL;
Step two, centrifuging the bacterial suspension, collecting bacterial sludge, adding the component I of the preparation solution into the bacterial sludge, wherein the volume ratio of the bacterial sludge to the component I is 1:4, and fully and uniformly mixing to prepare a bacterial suspension II;
step three, adding the component II of the preparation solution into the bacterial suspension II, and uniformly mixing to obtain a bacterial suspension III;
step four, placing the bacterial suspension III in a constant-temperature water bath kettle, standing for 30 min at 35 ℃, and performing vacuum freeze drying to obtain bacterial powder;
the first component of the preparation solution comprises the following components in percentage by mass: 10% of skim milk, 8% of trehalose, 4% of maltodextrin, 2% of sodium L-glutamate and the balance of water;
the second component of the preparation solution comprises: 2 '-fucosyllactose (2' -FL), wherein the adding volume of the 2 '-fucosyllactose (2' -FL) is 1% of that of the first component, and the second component is 10wt% of 2 '-fucosyllactose (2' -FL) aqueous solution;
the viable count of the bacterial powder is 10 11 CFU/mL。
The formula of the MRS culture medium is as follows: 5.0 g of peptone, 10.0 g of tryptone, 5.0 g of beef extract, 5.0 g of yeast powder, 20.0 g of glucose, 2.6 g of diammonium hydrogen citrate, 2.0 g of dipotassium hydrogen phosphate, 5.0 g of sodium acetate, 0.58 g of magnesium sulfate, 0.25 g of manganese sulfate and Tween-801 mL; the preparation method of the MRS culture medium comprises the following steps: accurately weighing the reagents according to the formula, fixing the volume in 1000 mL of distilled water, uniformly mixing, adjusting the pH value to 5.8, sterilizing at 121 ℃ for 15 min, and storing at 4 ℃ for later use.
The formula of the MRS solid culture medium is as follows: 10.0 g of peptone, 8.0 g of beef extract, 4.0 g of yeast powder, 20.0 g of glucose, 2.0 g of diammonium hydrogen citrate, 2.0 g of dipotassium hydrogen phosphate, 5.0 g of sodium acetate, 0.2 g of magnesium sulfate, 0.04 g of manganese sulfate, 14.0 g of agar and Tween-801 mL; the preparation method of the MRS solid culture medium comprises the following steps: accurately weighing the above reagents according to the above formula, fixing the volume in 1000 mL of distilled water, mixing well, adjusting pH to 5.8, sterilizing at 121 deg.C for 15 min,
putting into a constant temperature water bath kettle at 60 ℃ for standby.
The vacuum freeze drying process comprises the following steps: placing the treated bacterial suspension III into an ultra-low temperature refrigerator for pre-freezing at the temperature of minus 80 ℃ for 2 hours; and (3) starting the vacuum freeze dryer in advance, putting the pre-frozen bacterial suspension III on a partition plate of the vacuum freeze dryer, vacuumizing and freeze-drying, wherein the temperature of a cold trap of the freeze dryer is-53.2 ℃, the vacuum degree is 0.162 mbar, and the time is 24 hours.
The formulation obtained according to the preparation method described in this example.
Use of the formulation according to this example for the preparation of a medicament for ameliorating hepatic injury caused by a disturbance of glycolipid metabolism.
Use of a formulation according to this example in the manufacture of a medicament for ameliorating a disorder of glycolipid metabolism.
Example 3
This example differs from example 2 only in that: the first component comprises the following components in percentage by mass: 20% of skim milk, 12% of trehalose, 6% of maltodextrin, 4% of sodium L-glutamate and the balance of water;
the second component of the preparation solution comprises: 2 '-fucosyllactose (2' -FL), wherein the adding volume of the 2 '-fucosyllactose (2' -FL) is 3% of that of the first component, and the second component is 8wt% of 2 '-fucosyllactose (2' -FL) aqueous solution.
The above description is only of the preferred embodiments of the present invention, and it should be noted that: it will be apparent to those skilled in the art that various modifications and adaptations can be made without departing from the principles of the invention and these are intended to be within the scope of the invention.
Claims (8)
1. A preparation method of a Lactobacillus paracasei JY062 preparation is characterized by comprising the following steps:
step one, lactobacillus paracasei JY062 (Lactobacillus paracasei JY 062) is inoculated to an MRS culture medium in an inoculation amount of 5 percent, after the MRS culture medium is cultured for 16-18 h at the temperature of 32-37 ℃, three regions are scribed on the MRS solid culture medium, a single bacterial colony is selected to be placed in the MRS culture medium after the culture, after two generations of subculture, the bacterial colony is centrifuged at least for 10 min at 6000-8000 r/min, fermentation supernatant is collected, after the bacterial mud is washed at least twice by PBS, the bacterial mud is re-suspended by PBS, so that the viable count of the bacterial suspension at least reaches 10 9 CFU/mL;
Step two, centrifuging the bacterial suspension, collecting bacterial sludge, adding the component I of the preparation solution into the bacterial sludge, wherein the volume ratio of the bacterial sludge to the component I is 1:4, and fully and uniformly mixing to prepare a bacterial suspension II;
step three, adding the component II of the preparation solution into the bacterial suspension II, and uniformly mixing to obtain a bacterial suspension III;
step four, placing the bacterial suspension III in a constant-temperature water bath kettle, standing for at least 20 min at 35-37 ℃, and performing vacuum freeze drying to obtain bacterial powder;
the first component of the preparation solution comprises the following components in percentage by mass: 10-20% of skim milk, 8-12% of trehalose, 4-6% of maltodextrin, 2-4% of sodium L-glutamate and the balance of water;
the second component of the preparation solution comprises: 2' -fucosyllactose, wherein the adding volume of the 2' -fucosyllactose is 1-3% of that of the first component, and the second component is 5-10wt% of 2' -fucosyllactose aqueous solution;
the viable count of the bacterial powder is at least 1.23 × 10 11 CFU/mL。
2. The preparation method according to claim 1, wherein the formulation of the MRS medium is as follows: 5.0 g of peptone, 10.0 g of tryptone, 5.0 g of beef extract, 5.0 g of yeast powder, 20.0 g of glucose, 2.6 g of diammonium hydrogen citrate, 2.0 g of dipotassium hydrogen phosphate, 5.0 g of sodium acetate, 0.58 g of magnesium sulfate, 0.25 g of manganese sulfate and Tween-801 mL; the preparation method of the MRS culture medium comprises the following steps: accurately weighing the reagents according to the formula, fixing the volume in 1000 mL of distilled water, uniformly mixing, adjusting the pH value to 5.8, sterilizing at 121 ℃ for 15 min, and storing at 4 ℃ for later use.
3. The preparation method according to claim 1, wherein the formulation of the MRS solid medium is as follows: 10.0 g of peptone, 8.0 g of beef extract, 4.0 g of yeast powder, 20.0 g of glucose, 2.0 g of diammonium hydrogen citrate, 2.0 g of dipotassium hydrogen phosphate, 5.0 g of sodium acetate, 0.2 g of magnesium sulfate, 0.04 g of manganese sulfate, 14.0 g of agar and Tween-801 mL; the preparation method of the MRS solid culture medium comprises the following steps: accurately weighing the above reagents according to the above formula, fixing the volume in 1000 mL of distilled water, mixing well, adjusting pH to 5.8, sterilizing at 121 deg.C for 15 min,
putting into a constant temperature water bath kettle at 60 ℃ for standby.
4. The preparation method according to claim 1, wherein the vacuum freeze-drying process comprises: placing the treated bacterial suspension III into an ultra-low temperature refrigerator for pre-freezing at the temperature of minus 80 ℃ for 2 hours; and (3) starting the vacuum freeze dryer in advance, putting the pre-frozen bacterial suspension III on a partition plate of the vacuum freeze dryer, vacuumizing and freeze-drying, wherein the temperature of a cold trap of the freeze dryer is-53.2 ℃, the vacuum degree is 0.162 mbar, and the time is 24 hours.
5. The method of claim 1, wherein the PBS is 0.1mol/L and the pH value is 6.8.
6. The preparation obtained by the production method according to any one of claims 1 to 5.
7. Use of the formulation of claim 6 in the manufacture of a medicament for ameliorating a disorder of glycolipid metabolism.
8. Use of the formulation of claim 6 for the manufacture of a medicament for ameliorating hepatic injury caused by a disturbance of glycolipid metabolism.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210944148.5A CN115011532B (en) | 2022-08-08 | 2022-08-08 | Lactobacillus paracasei JY062 preparation, and preparation method and application thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210944148.5A CN115011532B (en) | 2022-08-08 | 2022-08-08 | Lactobacillus paracasei JY062 preparation, and preparation method and application thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
CN115011532A true CN115011532A (en) | 2022-09-06 |
CN115011532B CN115011532B (en) | 2022-11-15 |
Family
ID=83066167
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210944148.5A Active CN115011532B (en) | 2022-08-08 | 2022-08-08 | Lactobacillus paracasei JY062 preparation, and preparation method and application thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN115011532B (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115501259A (en) * | 2022-09-22 | 2022-12-23 | 东北农业大学 | Composition for relieving ulcerative colitis and application |
CN116042477A (en) * | 2023-01-05 | 2023-05-02 | 东北农业大学 | Lactobacillus plantarum J26 composition, preparation method and application thereof in weight-losing products |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20170055736A (en) * | 2015-11-12 | 2017-05-22 | 다울친환경영농조합법인 | Cultivation Method of Environment-Friendly Agricultural Products Using Microorganism |
CN109528777A (en) * | 2018-12-25 | 2019-03-29 | 东北农业大学 | By the application for the composition that Lactobacillus rhamnosus and 2`- fucosyllactose form |
CN111286469A (en) * | 2018-12-10 | 2020-06-16 | 东北农业大学 | Preparation method of lactobacillus paracasei freeze-dried powder |
WO2021260162A1 (en) * | 2020-06-26 | 2021-12-30 | Société des Produits Nestlé S.A. | Synbiotic composition |
WO2022161865A1 (en) * | 2021-01-29 | 2022-08-04 | Societe Des Produits Nestle S.A. | Mixture of hmos and bifidobacteria |
-
2022
- 2022-08-08 CN CN202210944148.5A patent/CN115011532B/en active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20170055736A (en) * | 2015-11-12 | 2017-05-22 | 다울친환경영농조합법인 | Cultivation Method of Environment-Friendly Agricultural Products Using Microorganism |
CN111286469A (en) * | 2018-12-10 | 2020-06-16 | 东北农业大学 | Preparation method of lactobacillus paracasei freeze-dried powder |
CN109528777A (en) * | 2018-12-25 | 2019-03-29 | 东北农业大学 | By the application for the composition that Lactobacillus rhamnosus and 2`- fucosyllactose form |
WO2021260162A1 (en) * | 2020-06-26 | 2021-12-30 | Société des Produits Nestlé S.A. | Synbiotic composition |
WO2022161865A1 (en) * | 2021-01-29 | 2022-08-04 | Societe Des Produits Nestle S.A. | Mixture of hmos and bifidobacteria |
Non-Patent Citations (2)
Title |
---|
KRISTA SALLI ET AL.: "The efect of 2′-fucosyllactose on simulated infant gut microbiome and metabolites; a pilot study in comparison to GOS and lactose", 《SCIENTIFIC REPORTS》 * |
张雅硕等: "高活性副干酪乳杆菌冻干菌粉的制备及工艺优化", 《食品工业科技》 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115501259A (en) * | 2022-09-22 | 2022-12-23 | 东北农业大学 | Composition for relieving ulcerative colitis and application |
CN116042477A (en) * | 2023-01-05 | 2023-05-02 | 东北农业大学 | Lactobacillus plantarum J26 composition, preparation method and application thereof in weight-losing products |
CN116042477B (en) * | 2023-01-05 | 2024-01-30 | 东北农业大学 | Lactobacillus plantarum J26 composition, preparation method and application thereof in weight-losing products |
Also Published As
Publication number | Publication date |
---|---|
CN115011532B (en) | 2022-11-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN115011532B (en) | Lactobacillus paracasei JY062 preparation, and preparation method and application thereof | |
CN114317353B (en) | Lactobacillus plantarum ZJFFYJ 7 and application thereof | |
CN110964650B (en) | Bacterial strain for preventing and treating metabolic diseases and application thereof | |
CN113069475B (en) | Bacterial strain, composition and application | |
CN117603828B (en) | Lactobacillus rhamnosus LRa66 with blood glucose and blood lipid reducing functions and application thereof | |
Qian et al. | Effects of lactobacillus casei YBJ02 on lipid metabolism in hyperlipidemic mice | |
CN115216422B (en) | Lactobacillus rhamnosus and application thereof | |
CN109593678B (en) | Bifidobacterium longum YH295 and application thereof in preparing product for reducing abdominal obesity risk | |
JP7264531B2 (en) | Morganella-derived nanovesicles and uses thereof | |
CN115927045B (en) | Lactobacillus salivarius 069 with cholesterol reducing and liver injury relieving functions caused by hyperlipidemia and application thereof | |
CN114381395B (en) | Lactobacillus plantarum ZJFFN 1 and application thereof | |
CN113197921A (en) | Application of bifidobacterium lactis MN-Gup and microbial inoculum thereof in treating type 2 diabetes | |
CN115505551A (en) | Lactobacillus helveticus and application thereof in preventing or treating nephritis | |
CN116410887A (en) | Microorganism strain of chaetoviridae, medicament for preventing or treating metabolic diseases and application thereof | |
CN113337440B (en) | Lactobacillus salivarius MG-587 and application thereof | |
CN114561318A (en) | Lactobacillus murinus and application thereof in treatment of type II diabetes | |
CN116508993B (en) | Application of lactobacillus reuteri in preparation of probiotics with metabolism regulating effect | |
CN115125163B (en) | Lactobacillus casei and application thereof | |
CN114621896B (en) | Lactobacillus plantarum84-3 with blood sugar and blood fat reducing functions and application thereof | |
CN110464756A (en) | It is a kind of for adjusting the gegen qinlian decoction water extract of fat body | |
US20130189298A1 (en) | Novel yeast strain and the application thereof | |
CN115025132B (en) | Synbiotic composition and preparation method and application thereof | |
CN113604400B (en) | Novel lactobacillus YUYINGW with diabetes preventing or treating effect | |
WO2022213507A1 (en) | Bacterial strain, composition, drug for use in combination, and use | |
WO2023208223A1 (en) | Pharmaceutical composition, megasphaera, and use thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |